Engineering unnatural amino acids in peptide linkers enables cathepsin-selective antibody-drug conjugates for HER2-positive breast cancer.

RPEP-111582025Gorzeń, Oliwia; Łęcka, Maria; Ćwilichowska-Puślecka, Natalia; Majchrzak, Martyna; Horbach, Natalia; Wiśniewski, Jerzy; Jakimowicz, Piotr; Szpot, Paweł; Zawadzki, Marcin; Dołęga-Kozierowski, Bartosz; Kasprzak, Piotr; Turk, Boris; Drąg, Marcin; Groborz, Katarzyna M; Matkowski, Rafał; Poręba, Marcin

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Engineering unnatural amino acids in peptide linkers enables cathepsin-selective antibody-drug conjugates for HER2-positive breast cancer.

Journal of controlled release : official journal of the Controlled Release Society, 387, 114269

View on PubMed ↗Publisher’s paper ↗

Citation

Gorzeń, Oliwia; Łęcka, Maria; Ćwilichowska-Puślecka, Natalia; Majchrzak, Martyna; Horbach, Natalia; Wiśniewski, Jerzy; Jakimowicz, Piotr; Szpot, Paweł; Zawadzki, Marcin; Dołęga-Kozierowski, Bartosz; Kasprzak, Piotr; Turk, Boris; Drąg, Marcin; Groborz, Katarzyna M; Matkowski, Rafał; Poręba, Marcin. (2025). Engineering unnatural amino acids in peptide linkers enables cathepsin-selective antibody-drug conjugates for HER2-positive breast cancer.. Journal of controlled release : official journal of the Controlled Release Society, 387, 114269. https://doi.org/10.1016/j.jconrel.2025.114269